In a first for up­start syn­thet­ic bi­ol­o­gy field, Zymer­gen files for $100M IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Five years af­ter the syn­thet­ic bi­ol­o­gy com­pa­ny Zymer­gen raised $174 mil­lion from in­vestors by piquing in­ter­est in de­sign­er mi­crobes, the com­pa­ny has filed for an IPO.

The com­pa­ny pen­ciled in a $100 mil­lion raise, al­though that fig­ure has be­come a place­hold­er over the last year for life sci­ences com­pa­nies that have their eyes on much larg­er troves.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters